DK1206495T3 - Kimære polypeptider, fremgangsmåde til frembringelse og anvendelser deraf - Google Patents

Kimære polypeptider, fremgangsmåde til frembringelse og anvendelser deraf

Info

Publication number
DK1206495T3
DK1206495T3 DK00948017T DK00948017T DK1206495T3 DK 1206495 T3 DK1206495 T3 DK 1206495T3 DK 00948017 T DK00948017 T DK 00948017T DK 00948017 T DK00948017 T DK 00948017T DK 1206495 T3 DK1206495 T3 DK 1206495T3
Authority
DK
Denmark
Prior art keywords
production
chimeric polypeptides
chimeric
polypeptides
Prior art date
Application number
DK00948017T
Other languages
English (en)
Inventor
Hauke Lilie
Susanne Richter
Rainer Rudolph
Kay-Gunnar Stubenrauch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1206495T3 publication Critical patent/DK1206495T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624Disulfide-stabilized antibody (dsFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/22011Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/22011Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22023Virus like particles [VLP]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK00948017T 1999-08-02 2000-07-31 Kimære polypeptider, fremgangsmåde til frembringelse og anvendelser deraf DK1206495T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99115022A EP1074563A1 (en) 1999-08-02 1999-08-02 Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
PCT/EP2000/007378 WO2001009193A1 (en) 1999-08-02 2000-07-31 Chimeric polypeptides, method for production and uses thereof

Publications (1)

Publication Number Publication Date
DK1206495T3 true DK1206495T3 (da) 2007-06-11

Family

ID=8238697

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00948017T DK1206495T3 (da) 1999-08-02 2000-07-31 Kimære polypeptider, fremgangsmåde til frembringelse og anvendelser deraf

Country Status (17)

Country Link
US (1) US6437095B1 (da)
EP (2) EP1074563A1 (da)
JP (1) JP4011914B2 (da)
KR (1) KR100484084B1 (da)
CN (1) CN1184235C (da)
AR (1) AR021448A1 (da)
AT (1) ATE353921T1 (da)
AU (1) AU768645B2 (da)
BR (1) BR0012926A (da)
CA (1) CA2380569C (da)
DE (1) DE60033405T2 (da)
DK (1) DK1206495T3 (da)
ES (1) ES2280231T3 (da)
MX (1) MXPA02001139A (da)
TR (1) TR200200252T2 (da)
WO (1) WO2001009193A1 (da)
ZA (1) ZA200109746B (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US20030157091A1 (en) * 2002-02-14 2003-08-21 Dyax Corporation Multi-functional proteins
US7335361B2 (en) * 2003-06-09 2008-02-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine
US7550557B2 (en) 2003-08-29 2009-06-23 Louisiana Tech University Foundation, Inc. Multilayer films, coatings, and microcapsules comprising polypeptides
US7348399B2 (en) * 2003-08-29 2008-03-25 Louisiana Tech University Foundation, Inc. Nanofabricated polypeptide multilayer films, coatings, and microcapsules
US7544770B2 (en) * 2003-08-29 2009-06-09 Louisiana Tech Foundation, Inc. Multilayer films, coatings, and microcapsules comprising polypeptides
CA2587643C (en) * 2004-11-22 2013-09-24 Louisiana Tech University Foundation Method for designing polypeptides for the nanofabrication of thin films, coatings, and microcapsules by electrostatic layer-by-layer self assembly
ATE439868T1 (de) * 2004-12-17 2009-09-15 Koninkl Philips Electronics Nv Targetingmittel für molekulare bilderzeugung
KR20120108967A (ko) 2009-09-16 2012-10-05 제넨테크, 인크. 코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
CA2817448C (en) 2010-12-23 2019-01-22 F. Hoffmann-La Roche Ag Binding agent
WO2012085064A1 (en) 2010-12-23 2012-06-28 Roche Diagnostics Gmbh Detection of a posttranslationally modified polypeptide by a bi-valent binding agent
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
WO2012085069A2 (en) 2010-12-23 2012-06-28 Roche Diagnostics Gmbh Detection of a polypeptide dimer by a bivalent binding agent
WO2012107932A1 (en) * 2011-02-11 2012-08-16 Transgene Biotek Ltd. B cell clonal immunotoxin and use thereof
CA2837914A1 (en) 2011-06-15 2012-12-20 F. Hoffmann-La Roche Ag Anti-human epo receptor antibodies and methods of use
WO2013119966A2 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
CA2871386A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
MX354862B (es) 2012-06-27 2018-03-23 Hoffmann La Roche Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
CN106795214B (zh) 2014-03-20 2022-09-02 百时美施贵宝公司 稳定化的基于纤连蛋白的支架分子
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
ES2981335T3 (es) 2014-11-25 2024-10-08 Bristol Myers Squibb Co Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
CN113563468A (zh) 2014-12-19 2021-10-29 雷根尼桑斯公司 结合人c6的抗体及其用途
US10983128B2 (en) 2015-02-05 2021-04-20 Bristol-Myers Squibb Company CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
TN2019000101A1 (en) 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
ES2809125T3 (es) 2015-09-23 2021-03-03 Bristol Myers Squibb Co Moléculas de armazón a base de fibronectina de unión a glipicano-3
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
KR20230038311A (ko) 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
US11344639B2 (en) 2016-06-01 2022-05-31 Bristol-Myers Squibb Company PET imaging with PD-L1 binding polypeptides
MY200602A (en) 2016-07-14 2024-01-04 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
WO2018083538A1 (en) 2016-11-07 2018-05-11 Neuracle Scienc3 Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
TWI788321B (zh) * 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
JP7076059B2 (ja) 2017-06-27 2022-05-27 ニューラクル サイエンス カンパニー リミテッド 抗fam19a5抗体及びその用途
KR20250078626A (ko) 2018-01-12 2025-06-02 브리스톨-마이어스 스큅 컴퍼니 Tim3에 대한 항체 및 그의 용도
PE20210665A1 (es) 2018-03-23 2021-03-31 Bristol Myers Squibb Co Anticuerpos contra mica y/o micb y sus usos
EP3774902A1 (en) 2018-04-02 2021-02-17 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
WO2020003210A1 (en) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anti-l1cam antibodies and uses thereof
CA3117619A1 (en) 2019-01-02 2020-07-09 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
US11008395B2 (en) 2019-01-22 2021-05-18 Bristol Myers-Squibb Company Antibodies against IL-7R alpha subunit and uses thereof
CN111655734A (zh) * 2019-04-28 2020-09-11 广州市雷德生物科技有限公司 一种促进蛋白二聚体形成的拉链扣结构及其应用
JP7796005B2 (ja) 2019-07-15 2026-01-08 ブリストル-マイヤーズ スクイブ カンパニー 抗trem-1抗体およびその使用
CN114144435B (zh) 2019-07-15 2024-06-25 百时美施贵宝公司 针对人trem-1的抗体及其用途
CN112694527B (zh) * 2020-12-25 2022-09-09 山东睿鹰制药集团有限公司 一种重组人干扰素-κ包涵体的纯化和复性方法
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型cdcp1に対する抗体およびその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK132892D0 (da) * 1992-10-30 1992-10-30 Novo Nordisk As Proteiner
US5747654A (en) * 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
JP4213224B2 (ja) * 1997-05-02 2009-01-21 ジェネンテック,インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法

Also Published As

Publication number Publication date
AU768645B2 (en) 2003-12-18
JP2003506028A (ja) 2003-02-18
DE60033405T2 (de) 2007-10-31
JP4011914B2 (ja) 2007-11-21
ATE353921T1 (de) 2007-03-15
MXPA02001139A (es) 2002-08-20
ES2280231T3 (es) 2007-09-16
ZA200109746B (en) 2003-03-12
CA2380569A1 (en) 2001-02-08
CN1184235C (zh) 2005-01-12
US6437095B1 (en) 2002-08-20
KR20020026558A (ko) 2002-04-10
CA2380569C (en) 2008-01-22
KR100484084B1 (ko) 2005-04-20
WO2001009193A1 (en) 2001-02-08
AU6161000A (en) 2001-02-19
BR0012926A (pt) 2002-04-30
AR021448A1 (es) 2002-07-17
EP1206495B1 (en) 2007-02-14
EP1074563A1 (en) 2001-02-07
CN1358198A (zh) 2002-07-10
DE60033405D1 (de) 2007-03-29
EP1206495A1 (en) 2002-05-22
TR200200252T2 (tr) 2002-05-21

Similar Documents

Publication Publication Date Title
DK1206495T3 (da) Kimære polypeptider, fremgangsmåde til frembringelse og anvendelser deraf
NO20012158D0 (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
DK1259547T3 (da) Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
IS6182A (is) A-beta peptíði og ferli til að búa þær til
DK1185536T3 (da) Hemisyntesefremgangsmåde og mellemprodukter deraf
DK1436309T3 (da) BGL3-beta-glukosidase og nukleinsyrer kodende derfor
NO20001330D0 (no) Produksjonsmetode for hydrater og anordning for utførelse av samme
IS6487A (is) Aðferð til framleiðslu á Sítalóprami
IS5884A (is) Aðferð til framleiðslu á hreinu sítalóprami
IS5982A (is) Aðferð til framleiðslu á 5-sýanóþalíði
DK1261697T3 (da) Kuldeaktiv beta-galactosidase, fremgangsmåde til fremstilling heraf og anvendelsen deraf
DK1322597T3 (da) Fremgangsmåde og intermediære
NO20022605D0 (no) Kjemiske fremgangsmåter og mellomprodukter
NO20051875D0 (no) Kjoleror og fremgangsmate for bruk av dette
DK1578738T3 (da) Escitalopram-hydrobromid og fremgangsmåde til fremstilling deraf
DK1399424T3 (da) Fremgangsmåde til fremstilling af 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepin-5-carboxamid og 10,11-dihydro-10-oxo-5H-dibenz[b,f]azepin-5-carboxamid
DE60044525D1 (de) Gassensor und dessen Herstellungsverfahren
MXPA03008005A (es) Metodo para la coloracion de material poroso.
NO20000383L (no) Forlengingsrørsammenstilling og fremgangsmÕte til setting av samme
GB0115204D0 (en) Ceramic materials, method for their production and use thereof
NO20010254L (no) Komposittprodukt og fremgangsmåte til fremstilling av dette
DK1361797T3 (da) Cremet næringsmiddel og fremgangsmåde til fremstilling deraf
IS6068A (is) Nýtt súrheyshjálparefni, aðferð til að framleiða þetta súrheyshjálparefni og notkun þessa súrheyshjálparefnis
GB2384779B (en) Method for the production of tagged proteins
AU2002365189A8 (en) P85-alpha nucleic acids, polypeptides and related methods